

# Angelika Eggert

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8845270/angelika-eggert-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

230  
papers

9,660  
citations

55  
h-index

91  
g-index

261  
ext. papers

11,650  
ext. citations

7.2  
avg. IF

5.43  
L-index

#	Paper	IF	Citations
230	Personalisierte Medizin in der Kinderonkologie: Wo stehen wir heute?. <i>Tumor Diagnostik Und Therapie</i> , <b>2022</b> , 43, 29-44	0.1	
229	Targeted analysis of cell-free circulating tumor DNA is suitable for early relapse and actionable target detection in patients with neuroblastoma.. <i>Clinical Cancer Research</i> , <b>2022</b> ,	12.9	6
228	Circulating Cell-Free DNA Assessment in Biofluids from Children with Neuroblastoma Demonstrates Feasibility and Potential for Minimally Invasive Molecular Diagnostics.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
227	Personalisierte Medizin in der Kinderonkologie: Wo stehen wir heute?. <i>Onkologie Up2date</i> , <b>2022</b> , 4, 181-198		
226	Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance. <i>PLoS Computational Biology</i> , <b>2021</b> , 17, e1009515	5	0
225	Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions. <i>Nature Communications</i> , <b>2021</b> , 12, 6804	17.4	8
224	Das Deutsche Konsortium für Translationale Krebsforschung <b>2021</b> , 36, 465-473	0.2	
223	Yoga, Meditation and Mindfulness in pediatric oncology - A review of literature. <i>Complementary Therapies in Medicine</i> , <b>2021</b> , 63, 102791	3.5	2
222	Comparing efficacy and side effects of two systemic chemotherapy regimens for eye-preserving therapy in children with retinoblastoma. <i>Pediatric Blood and Cancer</i> , <b>2021</b> , e29362	3	0
221	Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 322	12.8	4
220	Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG). <i>Pediatric Blood and Cancer</i> , <b>2021</b> , 68, e28963	3	1
219	CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
218	Eye Tumors in Childhood as First Sign of Tumor Predisposition Syndromes: Insights from an Observational Study Conducted in Germany and Austria. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
217	A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
216	External application of liver compresses to reduce fatigue in patients with metastatic cancer undergoing radiation therapy, a randomized clinical trial. <i>Radiation Oncology</i> , <b>2021</b> , 16, 76	4.2	2
215	ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3507-3509	12.9	1
214	Germline Mutations Including the Rare Pathogenic Variant c.3206delC in the Gene Cause Ataxia Teleangiectasia-Associated Primary Central Nervous System Lymphoma. <i>Children</i> , <b>2021</b> , 8,	2.8	1

213	A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 689697	8.4	2
212	Discovery of Spatial Peptide Signatures for Neuroblastoma Risk Assessment by MALDI Mass Spectrometry Imaging. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
211	GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma <b>2021</b> , 9,		2
210	Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 1219-1232	7.5	2
209	Long-term follow-up of children with neuroblastoma receiving radiotherapy to metastatic lesions within the German Neuroblastoma Trials NB97 and NB2004. <i>Strahlentherapie Und Onkologie</i> , <b>2021</b> , 197, 683-689	4.3	4
208	Allogeneic hematopoietic stem cell transplantation from sibling and unrelated donors in pediatric patients with sickle cell disease-A single center experience. <i>Pediatric Transplantation</i> , <b>2021</b> , 25, e13892	1.8	1
207	Development of an Integrative Care Program in a Pediatric Oncology Unit. <i>Complementary Medicine Research</i> , <b>2021</b> , 28, 131-138	1.3	2
206	Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma. <i>Children</i> , <b>2021</b> , 8,	2.8	1
205	Neuroblastom. <i>Springer Reference Medizin</i> , <b>2021</b> , 1-14	0	
204	Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , <b>2021</b> , 36, 1282-1289	5.6	0
203	Perception of integrative care in paediatric oncology-perspectives of parents and patients. <i>Complementary Therapies in Medicine</i> , <b>2021</b> , 56, 102624	3.5	3
202	Combined inhibition of Aurora-A and ATR kinase results in regression of -amplified neuroblastoma. <i>Nature Cancer</i> , <b>2021</b> , 2, 312-326	15.4	7
201	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2764-2779	24.4	22
200	Personalisierte Medizin in der Kinderonkologie: Wo stehen wir heute?. <i>Pädiatrie Up2date</i> , <b>2021</b> , 16, 325-342		
199	Multiplexed Quantification of Four Neuroblastoma DNA Targets in a Single Droplet Digital PCR Reaction. <i>Journal of Molecular Diagnostics</i> , <b>2020</b> , 22, 1309-1323	5.1	9
198	Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. <i>Annals of Oncology</i> , <b>2020</b> , 31, 422-429	10.3	19
197	Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology. <i>Cancers</i> , <b>2020</b> , 12,	6.6	12
196	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. <i>European Journal of Cancer</i> , <b>2020</b> , 136, 52-68	7.5	14

195	Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS). <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 953-960	4.9	7
194	Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4 CAR T Cell Efficacy. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 531	8.4	7
193	Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells. <i>Molecular Carcinogenesis</i> , <b>2020</b> , 59, 724-735	5	4
192	A Novel Standard for Systematic Reporting of Neuroblastoma Surgery: The International Neuroblastoma Surgical Report Form (INSRF): A Joint Initiative by the Pediatric Oncological Cooperative Groups SIOPEN*, COG**, and GPOH**. <i>Annals of Surgery</i> , <b>2020</b> , 275,	7.8	3
191	Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors. <i>Translational Oncology</i> , <b>2020</b> , 13, 221-232	4.9	8
190	Donor selection in a pediatric stem cell transplantation cohort using PIRCHE and HLA-DPB1 typing. <i>Pediatric Blood and Cancer</i> , <b>2020</b> , 67, e28127	3	1
189	Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma. <i>Nature Genetics</i> , <b>2020</b> , 52, 29-34	36.3	70
188	More than just warmth-The perception of warmth and relaxation through warming compresses. <i>Complementary Therapies in Medicine</i> , <b>2020</b> , 54, 102537	3.5	2
187	Evaluation of an Integrative Care Program in Pediatric Oncology. <i>Integrative Cancer Therapies</i> , <b>2020</b> , 19, 1534735420928393	3	3
186	Melanozytäre Naevi der Haut bei einem Neugeborenen. <i>Der Gynakologe</i> , <b>2020</b> , 53, 554-556	0.1	
185	LifeTime and improving European healthcare through cell-based interceptive medicine. <i>Nature</i> , <b>2020</b> , 587, 377-386	50.4	56
184	Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma. <i>Nature Communications</i> , <b>2020</b> , 11, 5823	17.4	34
183	Fast, In Vivo Model for Drug-Response Prediction in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Cancers</i> , <b>2020</b> , 12,	6.6	6
182	Towards a cancer mission in Horizon Europe: recommendations. <i>Molecular Oncology</i> , <b>2020</b> , 14, 1589-1615.9	15.9	15
181	Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma. <i>Children</i> , <b>2020</b> , 7,	2.8	
180	Transmission of chromosomally integrated human herpes virus-6A via haploidentical stem cell transplantation poses a risk for virus reactivation and associated complications. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 260-264	4.4	1
179	Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. <i>Leukemia</i> , <b>2020</b> , 34, 151-166	10.7	18
178	Reflection of neuroblastoma intratumor heterogeneity in the new OHC-NB1 disease model. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 1031-1041	7.5	3

177	Proton Beam Therapy for Children With Neuroblastoma: Experiences From the Prospective KiProReg Registry. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 617506	5.3	5
176	Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3493-3506	2.2	12
175	ADCC can improve graft vs leukemia effect after T- and B-cell depleted haploidentical stem cell transplantation in pediatric B-lineage ALL. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 689-693	4.4	3
174	CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. <i>BMC Cancer</i> , <b>2019</b> , 19, 895	4.8	23
173	Haploidentical CD3 or T-cell depleted HSCT in advanced stage sickle cell disease. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1859-1867	4.4	21
172	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. <i>European Journal of Cancer</i> , <b>2019</b> , 114, 27-35	7.5	28
171	HLA-haploidentical hematopoietic stem cell transplantation in pediatric patients with hemoglobinopathies: current practice and new approaches. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 743-748	4.4	10
170	A European paediatric cancer mission: aspiration or reality?. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 1200-1202	21.7	4
169	Prohibitin promotes de-differentiation and is a potential therapeutic target in neuroblastoma. <i>JCI Insight</i> , <b>2019</b> , 5,	9.9	8
168	Grundlagen der pädiatrischen Uroonkologie. <i>Springer Reference Medizin</i> , <b>2019</b> , 1-5	0	
167	Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma. <i>Cancer Letters</i> , <b>2019</b> , 445, 24-33	9.9	16
166	German Cancer Consortium (DKTK) - A national consortium for translational cancer research. <i>Molecular Oncology</i> , <b>2019</b> , 13, 535-542	7.9	12
165	Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET 12) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial. <i>Pediatric Blood and Cancer</i> , <b>2019</b> , 66, e27539	3	8
164	The landscape of genomic alterations across childhood cancers. <i>Nature</i> , <b>2018</b> , 555, 321-327	50.4	603
163	GADD45A and CDKN1A are involved in apoptosis and cell cycle modulatory effects of viscumTT with further inactivation of the STAT3 pathway. <i>Scientific Reports</i> , <b>2018</b> , 8, 5750	4.9	28
162	Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. <i>Leukemia</i> , <b>2018</b> , 32, 1657-1669	10.7	59
161	Stem Cell Transplantation in Advanced Stage Sickle Cell Disease with Haploidentical T-Cell Depleted PBSC Yields Comparable Outcomes to Matched Sibling Donor Bone Marrow: Results of a Pilot Study. <i>Blood</i> , <b>2018</b> , 132, 3455-3455	2.2	1
160	Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma. <i>Oncotarget</i> , <b>2018</b> , 9, 2304-2319	3.3	27

159	Assessment of Calcineurin Inhibitor-Associated Neurotoxicity in Patients with Sickle Cell Disease Receiving a Matched Sibling Donor or T-Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2018</b> , 132, 2088-2088	2.2	
158	High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. <i>Journal of Clinical Oncology</i> , <b>2018</b> , JCO2018782516	2.2	64
157	A mechanistic classification of clinical phenotypes in neuroblastoma. <i>Science</i> , <b>2018</b> , 362, 1165-1170	33.3	115
156	Integrative care for children with cancer. Project design for the development of an integrative care programme for use in paediatric oncology. <i>Complementary Therapies in Medicine</i> , <b>2018</b> , 41, 247-251	3.5	6
155	Immunotherapy with the trifunctional anti-CD20 anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 1989-1992	1.9	8
154	Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. <i>American Journal of Medical Genetics, Part A</i> , <b>2017</b> , 173, 1017-1037	2.5	124
153	Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. <i>Cell Death and Disease</i> , <b>2017</b> , 8, e2635	9.8	33
152	2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. <i>Klinische Padiatrie</i> , <b>2017</b> , 229, 147-167	0.9	48
151	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. <i>Expert Opinion on Drug Discovery</i> , <b>2017</b> , 12, 801-811	6.2	20
150	Synergistic Antitumour Properties of in Alveolar Rhabdomyosarcoma. <i>Journal of Immunology Research</i> , <b>2017</b> , 2017, 4874280	4.5	6
149	Using droplet digital PCR to analyze and copy number in plasma from patients with neuroblastoma. <i>Oncotarget</i> , <b>2017</b> , 8, 85234-85251	3.3	44
148	Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on I-MIBG SPECT predict the outcome?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 2203-2212 <sup>1</sup>	8.8	212 <sup>1</sup>
147	ViscumTT induces apoptosis and alters IAP expression in osteosarcoma in vitro and has synergistic action when combined with different chemotherapeutic drugs. <i>BMC Complementary and Alternative Medicine</i> , <b>2017</b> , 17, 26	4.7	15
146	Transcriptomic and proteomic insight into the effects of a defined European mistletoe extract in Ewing sarcoma cells reveals cellular stress responses. <i>BMC Complementary and Alternative Medicine</i> , <b>2017</b> , 17, 237	4.7	10
145	From class waivers to precision medicine in paediatric oncology. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e394-e404	40.7	35
144	Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center. <i>Pediatric Blood and Cancer</i> , <b>2017</b> , 64, 71-80	3	61
143	Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines. <i>Clinical and Experimental Ophthalmology</i> , <b>2017</b> , 45, 288-296	2.4	6
142	The INFORM personalized medicine study for high-risk pediatric cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 10509-10509	2.2	0

141	Targeting tachykinin receptors in neuroblastoma. <i>Oncotarget</i> , <b>2017</b> , 8, 430-443	3.3	11
140	The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. <i>Oncotarget</i> , <b>2017</b> , 8, 6730-6741	3.3	24
139	RITA displays anti-tumor activity in medulloblastomas independent of TP53 status. <i>Oncotarget</i> , <b>2017</b> , 8, 27882-27891	3.3	3
138	Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort. <i>Blood</i> , <b>2017</b> , 130, 898-898	2.2	
137	Embryonale Bauchtumoren im Kindes- und Jugendalter. <i>Onkologe</i> , <b>2016</b> , 22, 940-953	0.1	1
136	Pädiatrische Onkologie. <i>Onkologe</i> , <b>2016</b> , 22, 904-907	0.1	1
135	The SIOPE strategic plan: A European cancer plan for children and adolescents. <i>Journal of Cancer Policy</i> , <b>2016</b> , 8, 17-32	1	34
134	Minichromosome Maintenance Complex Is a Critical Node in the miR-183 Signaling Network of MYCN-Amplified Neuroblastoma Cells. <i>Journal of Proteome Research</i> , <b>2016</b> , 15, 2178-86	5.6	4
133	Regional hyperthermia combined with chemotherapy in paediatric, adolescent and young adult patients: current and future perspectives. <i>Radiation Oncology</i> , <b>2016</b> , 11, 65	4.2	19
132	Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2470-81	12.9	112
131	Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2. <i>PLoS ONE</i> , <b>2016</b> , 11, e0163648	3.7	4
130	MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. <i>Oncotarget</i> , <b>2016</b> , 7, 66344-66359	3.3	21
129	The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse. <i>Oncotarget</i> , <b>2016</b> , 7, 6620-5	3.3	7
128	Multiple Active Compounds from <i>Viscum album</i> L. Synergistically Converge to Promote Apoptosis in Ewing Sarcoma. <i>PLoS ONE</i> , <b>2016</b> , 11, e0159749	3.7	19
127	How Eye-Preserving Therapy Affects Long-Term Overall Survival in Heritable Retinoblastoma Survivors. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3183-8	2.2	30
126	Aktuelle Entwicklungen der pädiatrischen Onkologie [Neue Therapieoptionen, Versorgungskonzepte und Nachsorge. <i>Klinikarzt</i> , <b>2016</b> , 44, 635-642	0	3
125	Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. <i>European Journal of Cancer</i> , <b>2016</b> , 65, 91-101	7.5	186
124	Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. <i>Biomedical Reports</i> , <b>2015</b> , 3, 443-446	1.8	17



123	Mutational dynamics between primary and relapse neuroblastomas. <i>Nature Genetics</i> , <b>2015</b> , 47, 872-7	36.3	191
122	A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. <i>Oncogene</i> , <b>2015</b> , 34, 3357-68	9.2	74
121	Neoadjuvant/adjuvant treatment of high-risk retinoblastoma: a report from the German Retinoblastoma Referral Centre. <i>British Journal of Ophthalmology</i> , <b>2015</b> , 99, 949-53	5.5	13
120	Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 1215-27	7.4	14
119	Telomerase activation by genomic rearrangements in high-risk neuroblastoma. <i>Nature</i> , <b>2015</b> , 526, 700-4	50.4	347
118	miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 1308-20	7.5	65
117	Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 1308-14	1.9	4
116	MiR-34a deficiency accelerates medulloblastoma formation in vivo. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 2293-303	7.5	32
115	MYCN transcriptionally represses CD9 to trigger an invasion-metastasis cascade in neuroblastoma. <i>Molecular and Cellular Pediatrics</i> , <b>2015</b> , 2, A13	3.3	78
114	A Natural Combination Extract of <i>Viscum album</i> L. Containing Both Triterpene Acids and Lectins Is Highly Effective against AML In Vivo. <i>PLoS ONE</i> , <b>2015</b> , 10, e0133892	3.7	30
113	Neuroblastoma. <i>Critical Reviews in Oncogenesis</i> , <b>2015</b> , 20, 245-70	1.3	28
112	Temporal proteomics of NGF-TrkA signaling identifies an inhibitory role for the E3 ligase Cbl-b in neuroblastoma cell differentiation. <i>Science Signaling</i> , <b>2015</b> , 8, ra40	8.8	52
111	Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors. <i>Oncotarget</i> , <b>2015</b> , 6, 15425-35	3.3	24
110	CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients. <i>PLoS ONE</i> , <b>2014</b> , 9, e114696	3.7	14
109	Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2014</b> , 61, 1867-70	3	4
108	Impairment of bone health in pediatric patients with hemolytic anemia. <i>PLoS ONE</i> , <b>2014</b> , 9, e108400	3.7	15
107	Neuroblastoma in dialog with its stroma: NTRK1 is a regulator of cellular cross-talk with Schwann cells. <i>Oncotarget</i> , <b>2014</b> , 5, 11180-92	3.3	19
106	Long-term follow-up of pediatric patients receiving total body irradiation before hematopoietic stem cell transplantation and post-transplant survival of >2 years. <i>Pediatric Blood and Cancer</i> , <b>2013</b> , 60, 1792-7	3	29



105	Logic Learning Machine creates explicit and stable rules stratifying neuroblastoma patients. <i>BMC Bioinformatics</i> , <b>2013</b> , 14 Suppl 7, S12	3.6	17
104	MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. <i>Oncogene</i> , <b>2013</b> , 32, 1059-65	9.2	71
103	Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. <i>Oncogene</i> , <b>2013</b> , 32, 2927-36	9.2	72
102	The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma. <i>Acta Neuropathologica Communications</i> , <b>2013</b> , 1, 19	7.3	23
101	Discovery of a new bioactive molecule for neuroblastoma. <i>Chemical Biology and Drug Design</i> , <b>2013</b> , 82, 233-41	2.9	3
100	The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia. <i>BMC Cancer</i> , <b>2013</b> , 13, 452	4.8	7
99	MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 1064-73	7.5	84
98	Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. <i>International Journal of Cancer</i> , <b>2013</b> , 132, E106-15	7.5	21
97	Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre. <i>British Journal of Ophthalmology</i> , <b>2013</b> , 97, 1277-83	5.5	20
96	Targeted Therapy for Neuroblastoma: ALK Inhibitors. <i>Klinische Padiatrie</i> , <b>2013</b> , 225, 303-8	0.9	24
95	Whole-genome paired-end analysis confirms remarkable genomic stability of atypical teratoid/rhabdoid tumors. <i>Genes Chromosomes and Cancer</i> , <b>2013</b> , 52, 983-5	5	4
94	Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 908-19	7.5	16
93	Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction. <i>Scientific Reports</i> , <b>2013</b> , 3, 1351	4.9	24
92	Focal DNA copy number changes in neuroblastoma target MYCN regulated genes. <i>PLoS ONE</i> , <b>2013</b> , 8, e52321	3.7	31
91	BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. <i>Oncotarget</i> , <b>2013</b> , 4, 2080-95	3.3	97
90	Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. <i>Leukemia</i> , <b>2012</b> , 26, 2039-51	10.7	141
89	LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. <i>Nature Genetics</i> , <b>2012</b> , 44, 1199-206	36.3	273
88	Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas. <i>International Journal of Cancer</i> , <b>2012</b> , 130, 2599-606	7.5	31

87	The first European interdisciplinary ewing sarcoma research summit. <i>Frontiers in Oncology</i> , <b>2012</b> , 2, 54	5.3	29
86	Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. <i>Neuro-Oncology</i> , <b>2012</b> , 14, 859-69	1	44
85	Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF- $\alpha$ -independent apoptosis. <i>Cancer Research</i> , <b>2012</b> , 72, 2645-56	10.1	34
84	The metallophosphodiesterase Mpped2 impairs tumorigenesis in neuroblastoma. <i>Cell Cycle</i> , <b>2012</b> , 11, 569-81	4.7	24
83	Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 141ra91	17.5	119
82	Current concepts for diagnosis and treatment of retinoblastoma in Germany: aiming for safe tumor control and vision preservation. <i>Klinische Padiatrie</i> , <b>2012</b> , 224, 339-47	0.9	14
81	Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. <i>Oncogene</i> , <b>2012</b> , 31, 1571-81	9.2	44
80	Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 1409-17	8.7	19
79	The mentoring of women for medical career development. <i>International Journal of Mentoring and Coaching in Education</i> , <b>2012</b> , 1, 155-168	1.3	10
78	Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. <i>Oncogene</i> , <b>2011</b> , 30, 2823-35	9.2	23
77	Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research. <i>Seminars in Cancer Biology</i> , <b>2011</b> , 21, 217-28	12.7	56
76	Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma. <i>International Journal of Cancer</i> , <b>2011</b> , 129, 2390-9	7.5	32
75	miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7684-92	12.9	69
74	Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 731-41	12.9	60
73	High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5082-92	12.9	83
72	MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. <i>Oncogene</i> , <b>2010</b> , 29, 1394-404	9.2	104
71	Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q-neuroblastoma. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 2971-8	12.9	65
70	The quassinoid derivative NBT-272 targets both the AKT and ERK signaling pathways in embryonal tumors. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 3145-57	6.1	12

69	Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1532-41	12.9	69
68	Production of chick embryo extract for the cultivation of murine neural crest stem cells. <i>Journal of Visualized Experiments</i> , <b>2010</b> ,	1.6	14
67	Neuroblastoma: biology, prognosis, and treatment. <i>Hematology/Oncology Clinics of North America</i> , <b>2010</b> , 24, 65-86	3.1	279
66	Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. <i>Nucleic Acids Research</i> , <b>2010</b> , 38, 5919-28	20.1	166
65	Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4353-62	12.9	208
64	IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion. <i>Journal of Immunotherapy</i> , <b>2010</b> , 33, 200-10	5	76
63	Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. <i>International Journal of Cancer</i> , <b>2010</b> , 127, 2374-85	7.5	79
62	Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 2392-401	6.1	19
61	Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3690-6	12.9	37
60	Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. <i>Cancer Research</i> , <b>2009</b> , 69, 2065-71	10.1	358
59	Overall genomic pattern is a predictor of outcome in neuroblastoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1026-33	2.2	239
58	The low-affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells in vivo. <i>International Journal of Cancer</i> , <b>2009</b> , 124, 2488-94	7.5	13
57	Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness. <i>Oncogene</i> , <b>2009</b> , 28, 2015-23	5.4	54
56	MicroRNAs in the pathogenesis of neuroblastoma. <i>Cancer Letters</i> , <b>2009</b> , 274, 10-5	9.9	34
55	Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction. <i>Cancer Letters</i> , <b>2009</b> , 282, 55-62	9.9	10
54	Neuroblastom <b>2009</b> , 771-778		
53	Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma. <i>Oncogene</i> , <b>2008</b> , 27, 3329-38	9.2	45
52	CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23. <i>BMC Cancer</i> , <b>2008</b> , 8, 173	4.8	29

51	Expression of the TrkA or TrkB receptor tyrosine kinase alters the double-strand break (DSB) repair capacity of SY5Y neuroblastoma cells. <i>DNA Repair</i> , <b>2008</b> , 7, 1757-64	4.3	12
50	Neuroblastoma: biology, prognosis, and treatment. <i>Pediatric Clinics of North America</i> , <b>2008</b> , 55, 97-120, x	3.6	200
49	Transcription factor AP2alpha (TFAP2a) regulates differentiation and proliferation of neuroblastoma cells. <i>Cancer Letters</i> , <b>2008</b> , 271, 56-63	9.9	22
48	Microarray analysis of Ewing@ sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. <i>European Journal of Cancer</i> , <b>2008</b> , 44, 699-709	7.5	78
47	Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 1172-81	12.9	55
46	Photodynamic therapy in retinoblastoma: effects of verteporfin on retinoblastoma cell lines <b>2008</b> , 49, 3158-63		32
45	Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics. <i>International Journal of Cancer</i> , <b>2008</b> , 122, 1177-82	7.5	17
44	Neurotrophin receptor expression in human primary retinoblastomas and retinoblastoma cell lines. <i>Pediatric Blood and Cancer</i> , <b>2008</b> , 50, 218-22	3	16
43	MYCN regulates oncogenic MicroRNAs in neuroblastoma. <i>International Journal of Cancer</i> , <b>2008</b> , 122, 699-704	7.5	223
42	High resolution tiling-path BAC array deletion mapping suggests commonly involved 3p21-p22 tumor suppressor genes in neuroblastoma and more frequent tumors. <i>International Journal of Cancer</i> , <b>2007</b> , 120, 533-8	7.5	18
41	ArrayCGH-based classification of neuroblastoma into genomic subgroups. <i>Genes Chromosomes and Cancer</i> , <b>2007</b> , 46, 1098-108	5	62
40	Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 1459-65	12.9	27
39	The mutagenic potential of non-homologous end joining in the absence of the NHEJ core factors Ku70/80, DNA-PKcs and XRCC4-LigIV. <i>Mutagenesis</i> , <b>2007</b> , 22, 217-33	2.8	37
38	Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. <i>Cancer Research</i> , <b>2007</b> , 67, 2331-8	10.1	55
37	Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 2434-41	12.9	97
36	Vascular endothelial growth factor plasma levels are significantly elevated in patients with cerebral arteriovenous malformations. <i>Cerebrovascular Diseases</i> , <b>2006</b> , 21, 154-8	3.2	35
35	Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. <i>Genome Biology</i> , <b>2006</b> , 7, R84	18.3	111
34	VEGF plasma levels in non-ruptured intracranial aneurysms. <i>Neurosurgical Review</i> , <b>2006</b> , 29, 26-9	3.9	13

33	Application of microarray-based technology to neuroblastoma. <i>Cancer Letters</i> , <b>2005</b> , 228, 13-20	9.9	12
32	Phox2B mutations and the Delta-Notch pathway in neuroblastoma. <i>Cancer Letters</i> , <b>2005</b> , 228, 59-63	9.9	22
31	Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. <i>Cancer Letters</i> , <b>2005</b> , 228, 143-53	9.9	93
30	Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas. <i>Oncogene</i> , <b>2005</b> , 24, 165-77	9.2	67
29	Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. <i>Oncogene</i> , <b>2005</b> , 24, 6441-9	9.2	87
28	Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. <i>Oncogene</i> , <b>2005</b> , 24, 7902-12	9.2	100
27	Identification of dynamic proteome changes upon ligand activation of Trk-receptors using two-dimensional fluorescence difference gel electrophoresis and mass spectrometry. <i>Molecular and Cellular Proteomics</i> , <b>2005</b> , 4, 291-9	7.6	33
26	The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness. <i>Carcinogenesis</i> , <b>2005</b> , 26, 2105-15	4.6	47
25	Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia.. <i>Blood</i> , <b>2005</b> , 106, 1461-1461	2.2	
24	The Phox2B homeobox gene is mutated in sporadic neuroblastomas. <i>Oncogene</i> , <b>2004</b> , 23, 9280-8	9.2	97
23	Identification of New Markers for the Detection of Minimal Residual Disease in AML by Gene Expression Profiling and Real Time PCR.. <i>Blood</i> , <b>2004</b> , 104, 2008-2008	2.2	
22	Microarray-analysis: a new approach to study the molecular mechanisms of thermo-chemotherapy. <i>Klinische Padiatrie</i> , <b>2003</b> , 215, 298-302	0.9	9
21	Proteomics: techniques and applications in cancer research. <i>Klinische Padiatrie</i> , <b>2003</b> , 215, 293-7	0.9	11
20	Angiogenic cytokines. Quantitative and functional analysis. <i>Methods in Molecular Biology</i> , <b>2003</b> , 215, 117-133	1.4	0
19	Apoptosis induction by TRAIL. <i>Methods in Molecular Biology</i> , <b>2003</b> , 215, 95-116	1.4	
18	Expression of Apo-3 and Apo-3L in primitive neuroectodermal tumours of the central and peripheral nervous system. <i>European Journal of Cancer</i> , <b>2002</b> , 38, 92-8	7.5	21
17	Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma. <i>European Journal of Cancer</i> , <b>2002</b> , 38, 83-91	7.5	193
16	Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. <i>Cancer Research</i> , <b>2002</b> , 62, 1802-8	10.1	70

15	Resistance to chemotherapy mediated by TrkB in neuroblastomas. <i>Cancer Research</i> , <b>2002</b> , 62, 6462-6	10.1	155
14	TrkA signal transduction pathways in neuroblastoma. <i>Medical and Pediatric Oncology</i> , <b>2001</b> , 36, 108-10		9
13	Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas. <i>European Journal of Cancer</i> , <b>2001</b> , 37, 2064-72	7.5	59
12	Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in WilmsO tumor. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 689-96	2.2	87
11	Biological stability of RNA isolated from RNAlater-treated brain tumor and neuroblastoma xenografts. <i>Medical and Pediatric Oncology</i> , <b>2000</b> , 34, 438-42		50
10	Expression of neurotrophin receptor TrkA inhibits angiogenesis in neuroblastoma. <i>Medical and Pediatric Oncology</i> , <b>2000</b> , 35, 569-72		26
9	p75 mediated apoptosis in neuroblastoma cells is inhibited by expression of TrkA. <i>Medical and Pediatric Oncology</i> , <b>2000</b> , 35, 573-6		24
8	Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. <i>Medical and Pediatric Oncology</i> , <b>2000</b> , 35, 603-7		53
7	Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells. <i>Oncogene</i> , <b>2000</b> , 19, 2043-51	9.2	78
6	Relative quantitative RT-PCR protocol for TrkB expression in neuroblastoma using GAPD as an internal control. <i>BioTechniques</i> , <b>2000</b> , 28, 681-2, 686, 688-91	2.5	27
5	A novel human processed gene, DAD-R, maps to 12p12 and is expressed in several organs. <i>FEBS Letters</i> , <b>2000</b> , 473, 233-6	3.8	1
4	Different effects of TrkA expression in neuroblastoma cell lines with or without MYCN amplification. <i>Medical and Pediatric Oncology</i> , <b>2000</b> , 35, 623-7		14
3	Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. <i>Oncogene</i> , <b>2000</b> , 19, 4604-10	9.2	157
2	p75 mediated apoptosis in neuroblastoma cells is inhibited by expression of TrkA <b>2000</b> , 35, 573		2
1	Enhancer hijacking determines intra- and extrachromosomal circular MYCN amplicon architecture in neuroblastoma		1